<DOC>
	<DOCNO>NCT02029729</DOCNO>
	<brief_summary>This propose first-in-human study ( 408-C-1303 ) design assess safety , maximum tolerate dose , pharmacodynamics , pharmacokinetics omaveloxolone ( RTA 408 ) patient advance solid tumor refractory standard care therapy disease . The result study help provide clinical information design conduct clinical study RTA 408 cancer patient .</brief_summary>
	<brief_title>RTA 408 Treatment Advanced Solid Tumors ( NSCLC &amp; Melanoma ) - DISCOVER</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Adult male female patient ( 18 75 year age , inclusive ) ; 2 . Histologically cytologically document advanced NSCLC Stage IIIB/Stage IV disease , recurrent disease follow radiation therapy surgical resection advance , unresectable ( Stage III ) metastatic ( Stage IV ) melanoma ; 3 . Patients must experience disease recurrence progression prior treatment one prior standard systemic therapy ; 4 . Patients epidermal growth factor receptor ( EGFR ) overactivity mutation anaplastic lymphoma kinase ( ALK ) rearrangements must receive tyrosinekinase inhibitor ( TKI ) therapy prior consideration enrollment ; 5 . Life expectancy &gt; 3 month ; 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 ; 7 . Have discontinue previous treatment cancer recover acute toxic effect prior systemic therapy ( except alopecia ) grade ≤1 ; 8 . Have adequate bone marrow reserve organ function screen follow : 1 . Hematologic : Absolute neutrophil count &gt; 1.5 x 109/L , platelet &gt; 100 x 109/L , hemoglobin ≥ 9 g/dL ( Patients may receive erythrocyte transfusion achieve hemoglobin level discretion investigator . The first dose study drug must begin 5 day erythrocyte transfusion ) ; 2 . Hepatic : total bilirubin ≤ 1.5 X ULN , ALT AST ≤ ULN ; 3 . Renal : estimate glomerular filtration rate ( eGFR ) use modification diet renal disease ( MDRD ) formula ≥ 50 mL/min ; 9 . Willing practice method birth control ( male partner childbearing potential female childbearing potential ) screen 3 month take final dose RTA 408 ; 10 . Female patient childbearing potential must nonpregnant , nonlactating , negative pregnancy test result prior enrollment study ; 1 . Concurrent active malignancy adequately treat nonmelanomatous cell skin cancer , superficial bladder cancer , carcinoma situ cervix breast ; 2 . Patients previously brain metastasis ( screen require ) unless meet follow criterion : 1 . Patient resection and/or complete course cranial irradiation ; 2 . Patient worsen central nervous system symptom ; 3 . Patient discontinue corticosteroid indication least 2 week ; 3 . Cardiovascular abnormality : 1 . Evidence poor cardiovascular function define btype natriuretic peptide ( BNP ) &gt; 100 pg/mL , history congestive heart failure , unstable angina , uncontrolled hypertension , clinically significant ventricular arrhythmia screening ; 2 . Myocardial infarction within 6 month prior screen ; 3 . QTcF interval electrocardiogram ( ECG ) screen &gt; 450 msec male &gt; 460 female ; 4 . Known hepatic impairment include cirrhosis , know renal impairment include renal insufficiency glomerulonephritis severe cerebral peripheral vascular disease ; 5 . Any gastrointestinal disorder diarrhea major symptom , Crohn 's , pre exist chronic diarrhea CTCAE Grade ≥ 2 etiology . Included malabsorption disorder surgical procedure opinion investigator may affect absorption study drug ; 6 . Known active fungal , bacterial , and/or know viral infection include human immunodeficiency ( HIV ) viral ( A , B , C ) hepatitis ( screen require ) . ; 7 . Major surgery within 21 day Study Day 1 ; 8 . Have take follow drug within 7 day prior Study Day 1 : 1 . Sensitive substrate cytochrome P450 2C8 3A4 ( e.g. , repaglinide , midazolam , sildenafil ) ; 2 . Substrates pglycoprotein transporter ( e.g. , ambrisentan , digoxin ) , OCT1 transporter ( e.g. , metformin ) , OAT1 transporter ( e.g. , captopril , furosemide , methotrexate ) , OATP1B3 transporter ( e.g. , atorvastatin , rosuvastatin , valsartan ) ; 9 . Known suspected active drug alcohol abuse ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>RTA 408</keyword>
	<keyword>RTA 408 Capsules</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Metastatic non-small cell lung cancer</keyword>
	<keyword>Incurable non-small cell lung cancer</keyword>
	<keyword>Refractory melanoma</keyword>
	<keyword>Relapsed melanoma</keyword>
</DOC>